Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CT1812 Clear all
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of CT1812 in Healthy Volunteers

NCT03716427
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

NCT05225415
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 17, 2026, 2:59 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program for CT1812 (Zervimesine)

NCT06961760
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
zervimesine
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 86 Years
U.S. locations
8
States / cities
Sun City, Arizona • Palo Alto, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

NCT05893537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Active Comparator CT1812, Placebo Comparator
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

NCT05248672
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 17, 2026, 2:59 AM EDT